AcuCort has received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the study ZEQ001. The purpose of the study is to evaluate Zeqmelit® in acute allergic reactions and is part of the upcoming commercialization of the product in the Nordics. The study, which is a phase IV, open non-randomized low-intervention study, has as its overall objective to obtain real-world experience with Zeqmelit® from patients previously prescribed corticosteroids in tablet form for self-treatment of acute allergic reactions.

The study will provide information on availability, security with the treatment and perceived effect in the patients. The study is expected to start in the fourth quarter of 2023 and last until the second quarter of 2024.